133
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

, , ORCID Icon, , , ORCID Icon, , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1239-1246 | Published online: 25 Mar 2021

References

  • Mentis A, Lehours P, Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. 2015;20:1–7. doi:10.1111/hel.12250
  • Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19:S37.7762738
  • Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13:2–9. doi:10.1111/j.1751-2980.2011.00550.x22188910
  • Watari J, Chen N, Amenta PS, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol. 2014;20:5461–5473. doi:10.3748/wjg.v20.i18.546124833876
  • Cancer IAfRo. IARC monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. Vol 61. Lyon: World Health Organization, International Agency for Researchon Cancer (IARC); 1994.
  • Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. gastroenterology. 1996;110:1244–1252. doi:10.1053/gast.1996.v110.pm86130158613015
  • Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66:6–30.27707777
  • Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113–1114. e5. doi:10.1053/j.gastro.2016.01.02826836587
  • Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239. doi:10.1038/ajg.2016.56328071659
  • Sheu BS, Wu MS, Chiu CT, et al. Consensus on the clinical management, screening‐to‐treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017;22:e12368. doi:10.1111/hel.12368
  • Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019;25:6–14. doi:10.5056/jnm1813930504527
  • Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori treatment: a lesson from Japan or a limited geographic phenomenon? Front Pharmacol. 2019;10:316. doi:10.3389/fphar.2019.0031631024299
  • The European Committee on Antimicrobial Susceptibility Testing – EUCAST. Available from: https://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/. Accessed July 9, 2019.
  • Chuah SK, Liang CM, Lee CH, et al. A randomized control trial comparing 2 levofloxacin-containing second-line therapies for Helicobacter pylori eradication. Medicine. 2016;95:e3586. doi:10.1097/MD.000000000000358627175657
  • Yao CC, Kuo CM, Hsu CN, et al. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus. Infect Drug Resist. 2019;12:1425–1431. doi:10.2147/IDR.S19458431239721
  • Tai WC, Liang CM, Lee CH, et al. Seven-day nonbismuth containing quadruple therapy could achieve a grade “A” success rate for first-line Helicobacter pylori eradication. Biomed Res Int. 2015;2015:623732. doi:10.1155/2015/62373226090428
  • Tai WC, Liang CM, Kuo CM, et al. 14-day esomeprazole-and amoxicillin-containing high dose dual therapy achieves high eradication rate in the first line anti-helicobacter pylori treatment in Taiwan: a Prospective Randomized Trial. J Antimicrob Chemother. 2019;74:1718–1724. doi:10.1093/jac/dkz04630768161
  • Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori Infection. Clin Gastroenterol Hepatol. 2010;8:36–41. doi:10.1016/j.cgh.2009.09.03019804842
  • Tsay FW, Wu DC, Yu HC, et al. A randomized controlled trial shows that both 14- day hybrid and bismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with moderate antibiotic resistance. Antimicrob Agents Chemother. 2017;61. doi:10.1128/AAC.00140-17
  • Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol. 2004;38:503–506. doi:10.1097/01.mcg.0000129061.54277.c615220685
  • Choi HS, Park DI, Hwang SJ, et al. Double‐dose, new‐generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter. 2007;12:638–642. doi:10.1111/j.1523-5378.2007.00556.x18001407
  • Hsu PI, Lai K-H, Lin C-K, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005;100:2387–2392. doi:10.1111/j.1572-0241.2005.00264.x16279889
  • McNicholl A, Linares P, Nyssen O, Calvet X, Gisbert J. Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36:414–425. doi:10.1111/j.1365-2036.2012.05211.x22803691
  • Wilder-Smith C, Lind T, Lundin C, Naucler E, Nilsson-Pieschl C, Röhss K. Acid control with esomeprazole and lansoprazole: a comparative dose–response study. Scand J Gastroenterol. 2007;42:157–164. doi:10.1080/0036552060107584517327934
  • Graham DY, Lu H, Dore MP. Relative potency of proton‐pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double‐dose PPI. Helicobacter. 2019;24:e12554. doi:10.1111/hel.1255430440097
  • Sahara S, Sugimoto M, Uotani T, et al. Twice‐daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice‐daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013;38:1129–1137. doi:10.1111/apt.1249224099474
  • Shimatani T, Inoue M, Kuroiwa T, et al. Acid‐suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther. 2006;79:144–152. doi:10.1016/j.clpt.2005.09.01216413249
  • Erah P, Goddard A, Barrett D, Shaw P, Spiller R. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5–12. doi:10.1093/jac/39.1.59044021
  • Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology. 1996;111:358–367. doi:10.1053/gast.1996.v111.pm86902008690200
  • Chen L, He J, Wang L, et al. Efficacies of different proton pump inhibitor-based 14- day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clin Exp Med. 2018;18:569–576. doi:10.1007/s10238-018-0510-929876770
  • Boltin D, Levi Z, Gingold-Belfer R, et al. Comparative effect of proton-pump inhibitors on the success of triple and quadruple therapy for Helicobacter pylori infection. Dig Dis. 2020;38:408–414.31910424
  • Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(177–186):e3. doi:10.1016/j.cgh.2013.05.028
  • Liang CM, Tai WC, Hsu PI, et al. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol. 2020;13:1756284820976990. doi:10.1177/1756284820976990
  • Sakurai Y, Mori Y, Okamoto H, et al. Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects‐a randomised open‐label cross‐over study. Aliment Pharmacol Ther. 2015;42:719–730. doi:10.1111/apt.1332526193978
  • Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol. 2017;2017. doi:10.1155/2017/4385161
  • Sugimoto M, Yamaoka Y. Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Front Pharmacol. 2018;9:1560. doi:10.3389/fphar.2018.0156030697158